Nuveen’s Cyclerion Therapeutics CYCN Stock Holding History

Nuveen’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4,592	Closed	-$1.11M	–	3247
2019 Q3	$1.11M	Sell	4,592 -1,262	-22%	-$273K	﹤0.01%	2655
2019 Q2	$1.34M	Buy	+5,854	New	+$1.66M	﹤0.01%	2620

Other funds holding CYCN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AWH Capital Dallas, Texas $110M AUM 44.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen's CYCN Position: Q4 2019 in Review

Nuveen sold out of Cyclerion Therapeutics (CYCN) in Q4 2019, closing a stake of 4,592 shares — an estimated $1.11M sold.

Nuveen first reported a position in CYCN in Q2 2019 and held it in 2 quarters. The position peaked at $1.34M in Q2 2019. 77 funds tracked by Wall St. Rank hold CYCN as of Q4 2019.

Nuveen reported no remaining Cyclerion Therapeutics position as of Q4 2019 after selling out during the quarter.
Nuveen sold 4,592 Cyclerion Therapeutics shares in Q4 2019, an estimated $1.11M.
Nuveen first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 2 quarters.
Nuveen's Cyclerion Therapeutics position peaked at $1.34M in Q2 2019.
77 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2019.

Based on Nuveen's 13F filing for Q4 2019, filed 14 Feb 2020.